Detecting the virus HPV to predict the presence of cancer
Full project title: Novel plasma Human Papillomavirus DNA assay as a predictor of residual disease after chemo-radiotherapy for locally advanced head and neck cancer
Tag: Predictive tests
Dr Shree Bhide
Dr Jen Lee
Length of project:
Oracle Cancer Trust
The Institute of Cancer Research
As well as alcohol and tobacco, the human papilloma virus (HPV) is a known risk factor in head and neck cancer. HPV-positive head and neck cancer has been rising over the past 30 years and is set to continue, with a predicted increase of 230% in coming years.
In patients with HPV-positive head and neck cancer, it is not always clear from scans (PET-CT) if treatment with chemo-radiotherapy has been totally successful in clearing the cancer. In these cases, patients frequently undergo unnecessary neck dissection and repeated biopsies to make sure there is no disease remaining, also called residual disease. This causes significant morbidity.
Get in touch
Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: 80 Coombe Road, New Malden KT3 4QS